{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:02:59Z","timestamp":1784293379203,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15755-3","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:44:52Z","timestamp":1779497092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL20RB as a potential biomarker for prognosis in clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Li","family":"Yuehua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guiqiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Feiqiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"15755_CR1","doi-asserted-by":"crossref","unstructured":"Nicaise EH, Yildirim A, Sheth S, Richter E, Daneshmand MA, Maithel SK, Ogan K, Bilen MA, Master VA. Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma. CA Cancer J Clin. 2024.","DOI":"10.3322\/caac.21835"},{"issue":"6","key":"15755_CR2","first-page":"507","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507\u201324.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15755_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41573-023-00186-7","volume":"23","author":"J Tur","year":"2024","unstructured":"Tur J, Webster RM. The renal cell carcinoma drug market. Nat Rev Drug Discov. 2024;23(1):16\u20137.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"15755_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376(4):354\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"15755_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00210-023-02674-4","volume":"397","author":"A Wahi","year":"2024","unstructured":"Wahi A, Jain P, Sinhari A, Jadhav HR. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(2):675\u2013702.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"15755_CR6","doi-asserted-by":"publisher","first-page":"1327933","DOI":"10.3389\/fonc.2024.1327933","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Zheng D, Pu X, Li S. HDAC7: a promising target in cancer. Front Oncol. 2024;14:1327933.","journal-title":"Front Oncol"},{"issue":"1","key":"15755_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12967-024-05169-9","volume":"22","author":"M Xu","year":"2024","unstructured":"Xu M, Hou Y, Li N, Yu W, Chen L. Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets. J Transl Med. 2024;22(1):418.","journal-title":"J Transl Med"},{"key":"15755_CR8","doi-asserted-by":"crossref","unstructured":"Zhou L, Yu CW. Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment. Pharmacol Res. 2024:107205.","DOI":"10.1016\/j.phrs.2024.107205"},{"key":"15755_CR9","doi-asserted-by":"crossref","unstructured":"Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. Metabolomic profiling in renal cell carcinoma patients: news and views. Cancers (Basel). 2021;13(20).","DOI":"10.3390\/cancers13205229"},{"issue":"2","key":"15755_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12272-017-0998-7","volume":"41","author":"P Chun","year":"2018","unstructured":"Chun P. Therapeutic effects of histone deacetylase inhibitors on kidney disease. Arch Pharm Res. 2018;41(2):162\u201383.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"15755_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12863-022-01076-4","volume":"23","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu Y, Wang B, Wang C. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma. BMC Genom Data. 2022;23(1):58.","journal-title":"BMC Genom Data"},{"issue":"4","key":"15755_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1293\/tox.2019-0017","volume":"32","author":"XF Cui","year":"2019","unstructured":"Cui XF, Cui XG, Leng N. Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma. J Toxicol Pathol. 2019;32(4):245\u201351.","journal-title":"J Toxicol Pathol"},{"key":"15755_CR13","doi-asserted-by":"publisher","first-page":"4083735","DOI":"10.1155\/2016\/4083735","volume":"2016","author":"MK Wirtz","year":"2016","unstructured":"Wirtz MK, Keller KE. The role of the IL-20 subfamily in glaucoma. Mediators Inflamm. 2016;2016:4083735.","journal-title":"Mediators Inflamm"},{"issue":"12","key":"15755_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nri3766","volume":"14","author":"S Rutz","year":"2014","unstructured":"Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines--from host defence to tissue homeostasis. Nat Rev Immunol. 2014;14(12):783\u201395.","journal-title":"Nat Rev Immunol"},{"key":"15755_CR15","doi-asserted-by":"publisher","first-page":"915246","DOI":"10.3389\/fimmu.2022.915246","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, Yang G. IL22RA1\/JAK\/STAT Signaling Acts As a Cancer Target Through Pan-Cancer Analysis. Front Immunol. 2022;13:915246.","journal-title":"Front Immunol"},{"issue":"12","key":"15755_CR16","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.ejca.2011.04.012","volume":"47","author":"AM Baird","year":"2011","unstructured":"Baird AM, Gray SG, O\u2019Byrne KJ. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer. 2011;47(12):1908\u201318.","journal-title":"Eur J Cancer"},{"key":"15755_CR17","doi-asserted-by":"publisher","first-page":"9443407","DOI":"10.1155\/2022\/9443407","volume":"2022","author":"H Guo","year":"2022","unstructured":"Guo H, Jiang S, Sun H, Shi B, Li Y, Zhou N, et al. Identification of IL20RB as a novel prognostic and therapeutic biomarker in clear cell renal cell carcinoma. Dis Markers. 2022;2022:9443407.","journal-title":"Dis Markers"},{"key":"15755_CR18","doi-asserted-by":"publisher","first-page":"113959","DOI":"10.1016\/j.addr.2021.113959","volume":"177","author":"TKM Leong","year":"2021","unstructured":"Leong TKM, Lo WS, Lee WEZ, Tan B, Lee XZ, Lee L, et al. Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space. Adv Drug Deliv Rev. 2021;177:113959.","journal-title":"Adv Drug Deliv Rev"},{"key":"15755_CR19","doi-asserted-by":"crossref","unstructured":"Graham J, Dudani S, Heng DYC. Prognostication in kidney cancer: recent advances and future directions. J Clin Oncol. 2018:JCO2018790147.","DOI":"10.1200\/JCO.2018.79.0147"},{"key":"15755_CR20","doi-asserted-by":"crossref","unstructured":"Hage Chehade C, Agarwal N. Molecular subtypes as potential biomarkers in renal cell carcinoma. Cancer Cell. 2024.","DOI":"10.1016\/j.ccell.2024.04.003"},{"key":"15755_CR21","doi-asserted-by":"publisher","first-page":"101040","DOI":"10.1016\/j.currproblcancer.2023.101040","volume":"48","author":"D Hu","year":"2024","unstructured":"Hu D, Wang Y, Ji G, Liu Y. Using machine learning algorithms to predict the prognosis of advanced nasopharyngeal carcinoma after intensity-modulated radiotherapy. Curr Probl Cancer. 2024;48:101040.","journal-title":"Curr Probl Cancer"},{"key":"15755_CR22","doi-asserted-by":"crossref","unstructured":"Hassan J, Saeed SM, Deka L, Uddin MJ, Das DB. Applications of Machine Learning (ML) and Mathematical Modeling (MM) in healthcare with special focus on cancer prognosis and anticancer therapy: current status and challenges. Pharmaceutics. 2024;16(2).","DOI":"10.3390\/pharmaceutics16020260"},{"issue":"1","key":"15755_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-024-01315-6","volume":"16","author":"M Unger","year":"2024","unstructured":"Unger M, Kather JN. Deep learning in cancer genomics and histopathology. Genome Med. 2024;16(1):44.","journal-title":"Genome Med"},{"key":"15755_CR24","doi-asserted-by":"publisher","first-page":"1088931","DOI":"10.3389\/fonc.2022.1088931","volume":"12","author":"P Zhang","year":"2022","unstructured":"Zhang P, Pei S, Liu J, Zhang X, Feng Y, Gong Z, et al. Cuproptosis-related lncRNA signatures: predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma. Front Oncol. 2022;12:1088931.","journal-title":"Front Oncol"},{"key":"15755_CR25","doi-asserted-by":"crossref","unstructured":"Zhang P, Wang D, Zhou G, Jiang S, Zhang G, Zhang L, Zhang Z. Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma. J Immunother Cancer. 2025;13(2).","DOI":"10.1136\/jitc-2024-010787"},{"key":"15755_CR26","doi-asserted-by":"publisher","first-page":"643065","DOI":"10.3389\/fonc.2021.643065","volume":"11","author":"F Petitprez","year":"2021","unstructured":"Petitprez F, Ayadi M, de Reyni\u00e8s A, Fridman WH, Saut\u00e8s-Fridman C, Job S. Review of prognostic expression markers for clear cell renal cell carcinoma. Front Oncol. 2021;11:643065.","journal-title":"Front Oncol"},{"issue":"1","key":"15755_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12885-024-12183-z","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, He X, Mi Y, Chen YQ, Li J, Wang R. PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma. BMC Cancer. 2024;24(1):463.","journal-title":"BMC Cancer"},{"key":"15755_CR28","doi-asserted-by":"crossref","unstructured":"Braga EA, Fridman MV, Filippova EA, Loginov VI, Pronina IV, Burdennyy AM, Karpukhin AV, Dmitriev AA, Morozov SG. LncRNAs in the regulation of genes and signaling pathways through mirna-mediated and other mechanisms in clear cell renal cell carcinoma. Int J Mol Sci. 2021;22(20).","DOI":"10.3390\/ijms222011193"},{"issue":"12","key":"15755_CR29","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"22\u201323","key":"15755_CR30","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1093\/bioinformatics\/btaa1018","volume":"36","author":"X Lu","year":"2021","unstructured":"Lu X, Meng J, Zhou Y, Jiang L, Yan F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2021;36(22\u201323):5539\u201341.","journal-title":"Bioinformatics"},{"key":"15755_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"9","key":"15755_CR32","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468.","journal-title":"PLoS One"},{"issue":"8","key":"15755_CR33","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"15755_CR34","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"5","key":"15755_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529\u201342.","journal-title":"Eur Urol"},{"issue":"4","key":"15755_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.eururo.2023.07.006","volume":"84","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Rane PP, Saretsky TL, Pawar D, Martin Nguyen A, Sundaram M, et al. Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: a systematic literature review. Eur Urol. 2023;84(4):406\u201317.","journal-title":"Eur Urol"},{"issue":"10","key":"15755_CR37","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","volume":"9","author":"L Vuong","year":"2019","unstructured":"Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9(10):1349\u201357.","journal-title":"Cancer Discov"},{"issue":"10","key":"15755_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","volume":"16","author":"RR Kotecha","year":"2019","unstructured":"Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16(10):621\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15755_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"key":"15755_CR40","doi-asserted-by":"publisher","first-page":"102745","DOI":"10.1016\/j.ctrv.2024.102745","volume":"127","author":"M Tucci","year":"2024","unstructured":"Tucci M, Mandar\u00e0 M, Giuliani J, Durante E, Buttigliero C, Turco F, et al. Treatment options in first-line metastatic renal carcinoma: a meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials. Cancer Treat Rev. 2024;127:102745.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"15755_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/pharmrev.122.000612","volume":"75","author":"AM Mustafa","year":"2023","unstructured":"Mustafa AM, Kr\u00e4mer OH. Pharmacological modulation of the crosstalk between aberrant Janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharmacol Rev. 2023;75(1):35\u201361.","journal-title":"Pharmacol Rev"},{"key":"15755_CR42","doi-asserted-by":"publisher","first-page":"175216","DOI":"10.1016\/j.ejphar.2022.175216","volume":"931","author":"R Hai","year":"2022","unstructured":"Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol. 2022;931:175216.","journal-title":"Eur J Pharmacol"},{"key":"15755_CR43","doi-asserted-by":"publisher","first-page":"106181","DOI":"10.1016\/j.bioorg.2022.106181","volume":"129","author":"L Zhao","year":"2022","unstructured":"Zhao L, Liang Q, He Y, Liu M, Tong R, Jiang Z, et al. HDAC\/JAK dual target inhibitors of cancer-related targets: the success of nonclearable linked pharmacophore mode. Bioorg Chem. 2022;129:106181.","journal-title":"Bioorg Chem"},{"key":"15755_CR44","doi-asserted-by":"publisher","first-page":"123219","DOI":"10.1016\/j.ijbiomac.2023.123219","volume":"230","author":"YC Zheng","year":"2023","unstructured":"Zheng YC, Kang HQ, Wang B, Zhu YZ, Mamun MAA, Zhao LF, et al. Curriculum vitae of HDAC6 in solid tumors. Int J Biol Macromol. 2023;230:123219.","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"15755_CR45","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41416-019-0625-0","volume":"121","author":"Y Xue","year":"2019","unstructured":"Xue Y, Lian W, Zhi J, Yang W, Li Q, Guo X, et al. HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer. Br J Cancer. 2019;121(12):1039\u201349.","journal-title":"Br J Cancer"},{"issue":"1","key":"15755_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13058-024-01799-5","volume":"26","author":"SG Smoots","year":"2024","unstructured":"Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, et al. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin\/OKI-179 to promote apoptosis. Breast Cancer Res. 2024;26(1):35.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"15755_CR47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-020-01720-w","volume":"39","author":"J Li","year":"2020","unstructured":"Li J, Hu M, Liu N, Li H, Yu Z, Yan Q, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p\/TGIF1\/TGF\u03b2 axis. J Exp Clin Cancer Res. 2020;39(1):248.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"15755_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.eururo.2011.10.007","volume":"61","author":"AR Brannon","year":"2012","unstructured":"Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012;61(2):258\u201368.","journal-title":"Eur Urol"},{"issue":"1","key":"15755_CR49","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1038\/s41598-023-33954-x","volume":"13","author":"L Manganaro","year":"2023","unstructured":"Manganaro L, Bianco S, Bironzo P, Cipollini F, Colombi D, Cor\u00e0 D, et al. Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer. Sci Rep. 2023;13(1):7759.","journal-title":"Sci Rep"},{"issue":"1","key":"15755_CR50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12859-021-04279-1","volume":"22","author":"G Bri\u00e8re","year":"2021","unstructured":"Bri\u00e8re G, Darbo \u00c9, Th\u00e9bault P, Uricaru R. Consensus clustering applied to multi-omics disease subtyping. BMC Bioinformatics. 2021;22(1):361.","journal-title":"BMC Bioinformatics"},{"key":"15755_CR51","doi-asserted-by":"publisher","first-page":"105337","DOI":"10.1016\/j.cmpb.2020.105337","volume":"189","author":"J Li","year":"2020","unstructured":"Li J, Xie L, Xie Y, Wang F. Bregmannian consensus clustering for cancer subtypes analysis. Comput Methods Programs Biomed. 2020;189:105337.","journal-title":"Comput Methods Programs Biomed"},{"key":"15755_CR52","doi-asserted-by":"crossref","unstructured":"Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, McConkey DJ, Wei P, Czerniak B. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol. 2024.","DOI":"10.1038\/s41585-023-00847-7"},{"issue":"2","key":"15755_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","volume":"81","author":"W Choi","year":"2022","unstructured":"Choi W, Lombardo K, Patel S, Epstein G, Feng M, Gabrielson A, et al. A molecular inquiry into the role of antibody-drug conjugates in Bacillus Calmette-Gu\u00e9rin-exposed non-muscle-invasive bladder cancer. Eur Urol. 2022;81(2):138\u201342.","journal-title":"Eur Urol"},{"key":"15755_CR54","doi-asserted-by":"crossref","unstructured":"Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. 2024.","DOI":"10.1016\/j.ccell.2024.03.002"},{"issue":"1","key":"15755_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12929-023-00915-5","volume":"30","author":"Z Wu","year":"2023","unstructured":"Wu Z, Uhl B, Gires O, Reichel CA. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence. J Biomed Sci. 2023;30(1):21.","journal-title":"J Biomed Sci"},{"issue":"1","key":"15755_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14(1):45.","journal-title":"Genome Med"},{"issue":"4","key":"15755_CR57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","volume":"25","author":"RC Stassen","year":"2024","unstructured":"Stassen RC, Maas C, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, et al. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol. 2024;25(4):509\u201317.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15755_CR58","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41467-024-47926-w","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang H, Zhou Y, Li L, Lyu M, Wu C, et al. An individualized protein-based prognostic model to stratify pediatric patients with papillary thyroid carcinoma. Nat Commun. 2024;15(1):3560.","journal-title":"Nat Commun"},{"issue":"1","key":"15755_CR59","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1186\/s12967-023-04800-5","volume":"21","author":"XH Li","year":"2023","unstructured":"Li XH, Huang GZ, Xu ZL, Zhao CY, Dong XY, Cui BK, et al. IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer. J Transl Med. 2023;21(1):911.","journal-title":"J Transl Med"},{"key":"15755_CR60","doi-asserted-by":"crossref","unstructured":"He Y, Luo W, Liu Y, Wang Y, Ma C, Wu Q, Tian P, He D, Jia Z, Lv X et al. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer. J Clin Invest. 2022;132(20).","DOI":"10.1172\/JCI157917"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15755-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:04:19Z","timestamp":1784289859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15755-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15755"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15755-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Chongqing Traditional Chinese Medicine Hospital (approval NO.: CTCMH20230410) and conducted following the Helsinki Declaration. Written informed consent was obtained from individual or guardian participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"862"}}